Skip to Primary Navigation

Skip to main content

Affordability and innovation are focus of Senate Dems’ drug-pricing proposals

A photo of Ranking Member Sen. Ron Wyden (D-OR) of the Senate Finance Committee.
Photo: Anna Moneymaker/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Just in time for midterm elections, a new RFI seeks public input on Medicare drug pricing negotiations, inflation-based rebates, and supply-chain oversight.

Democrats on the Senate Finance Committee have released a request for information (RFI) outlining potential federal policy changes aimed at reshaping prescription drug pricing with a focus on affordability and innovation.

The 42-page RFI seeks stakeholder input on proposals that would modify Medicare negotiation rules, adjust inflation‑based rebate requirements, and

, , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience